Cargando…
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
OBJECTIVE: We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic complete response (pCR, ypT0/is ypN0) in patients with HR+/HER2+, HR-/HER2-or HR-/HER2+ early breast cancer enrolled in the WSG-ADAPT su...
Autores principales: | Graeser, Monika, Harbeck, Nadia, Gluz, Oleg, Würstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva-Maria, Forstbauer, Helmut, Dimpfl, Moritz, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kümmel, Sherko, Nitz, Ulrike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239457/ https://www.ncbi.nlm.nih.gov/pubmed/34166854 http://dx.doi.org/10.1016/j.breast.2021.06.001 |
Ejemplares similares
-
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021) -
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021) -
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022) -
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
por: Graeser, Monika, et al.
Publicado: (2021) -
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
por: Harbeck, Nadia, et al.
Publicado: (2021)